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Abstract 
 
Scientific background. Long-acting injectable antipsychotics (LAIs) are considered 
one of the most important tools for ensuring medication adherence in people with 
chronic psychosis. In recent times many authors promoted an earlier and broader use 
of LAIs, considering not only their efficacy in preventing non-adherence (and 
therefore relapses), but also their potential role in simplifying the daily medication 
routine, ultimately ameliorating patient’s quality of life. On this background, this 
study aims at describing how this new perspective influenced prescribing pattern in 
Community Psychiatry Services, with a specific interest in comparing first- and 
second-generation antipsychotics. 
Methods. The STAR Network “Depot” Study is an observational, longitudinal, 
multicenter study involving 35 Italian Community Psychiatry Services. Adult patients 
initiating a new LAI were recruited over a 12-months period and assessed for 
relevant socio-demographic and clinical features (employing also validated rating 
scales) at baseline, after 6 and 12 months. Descriptive statistics and a stepped 
multivariate logistic model accounting for the inter-center variability were employed. 
Results. Only results from the recruitment (or cross-sectional) phase will be 
discussed here. Four-hundred-fifty-one patients, mostly males over their 30s, were 
recruited. Patients were heterogeneously distributed between higher and lower levels 
of education, social functioning, overall symptom profiles and medication adherence. 
Beside schizophrenia, also bipolar disorders, personality disorders and mental organic 
conditions were well represented. Paliperidone and aripiprazole were the most 
frequently prescribed medications. Analyses showed that, compared to first-
generation LAIs, second-generation LAIs were more likely to be prescribed to 
younger, employed patients, with higher affective symptoms, a diagnosis different 
from schizophrenia or bipolar disorder, and fewer previous LAI prescriptions. 
Discussion. LAIs are prescribed to heterogeneous populations of patients, often 
even off-label. The advocated paradigm shift is under way in clinical practice, 
although it appears to be largely limited to second-generation LAIs. 
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Introduction 
 
In recent years, many authors highlighted the potential advantages of a broader and 
earlier prescription of long-acting injectable antipsychotics (LAIs) based on several 
assumptions, including (a) the growing evidence of their superiority in preventing 
relapses, hospitalization and lack of adherence, as compared to oral antipsychotics, 
which is of utmost relevance in the early stages of disease; (b) the progressive 
overcoming of old misconceptions about the perceived coercion and stigma 
associated with these formulations; and (c) the growing awareness that the 
practicality of LAIs may contribute to considerably simplify the daily routine of 
patients, possibly ameliorating their overall quality of life and even their global 
attitude toward psychotropic medication. Also, the scenario widely changed in the 
last decade, considering the progressive introduction of second-generation 
antipsychotics (SGAs) LAIs on the market, and, in general, a growing interest in the 
use of SGAs not only for the treatment of schizophrenia and related chronic 
psychosis, but also for bipolar disorder and resistant depression. 
The STAR Network “Depot” study was designed with the aim of describing a 
population of patients initiating a new LAI in Italian Community Psychiatric Services 
and to longitudinally assess their clinical status, as well as adherence and subjective 
perception of medications over one year of treatment. The first phase focused on 
describing socio-demographic and clinical features this cohort of patients at baseline, 
with the ultimate goal of evaluating prescribing patterns of LAIs, and to assess 
whether and how the new perspective on their clinical employment was actually 
implemented in clinical practice. Relevant features of the cohort will be described in 
detail, and possible associations between these features and the choice of FGA 
versus SGA LAIs will be explored using a stepped logistic analysis. Results will be 
critically discussed in the light of available scientific evidence, methodological 
advantages and pitfalls, current clinical guidelines, regulatory implications, as well as 
factors specifically related to the setting of care. 
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Chapter 1 
Scientific Background 
 
The problem of both hidden and overt non-adherence to medications is of major 
concern in mental health, and particularly in patients with psychotic disorders (Nosé 
et al., 2003), leading to severe consequences on the disease’s course (Stevens et al., 
2016; Kirschner et al., 2013; Stahl, 2014). It is estimated that up to 40% of patients 
will autonomously suspend the antipsychotic medication within one year from its 
introduction, and about four over five of these patients will experience a disease 
relapse within the following five years. Furthermore, the number of psychotics 
relapses during the first five years of disease is associated a higher risk of chronic 
course of disease, functional impairment, social and relational withdrawal, and 
irreversible brain damage. This is particularly worrisome considering that the actual 
level of adherence is likely to be usually underestimated by clinicians. Patients’ 
attitudes toward psychotropic medications and their level of adherence are complex 
and multifaceted constructs, in which many interacting factors come into play 
(Nunes et al., 2009) (Figure 1). 
 
Figure 1. Internal and external factor involved in determining therapy adherence and attitudes 
toward psychotropic medications. From Horne, R. Concordance, Adherence and Compliance in 
Medicine Taking. Report for the National Co-ordinating Centre for NHS Service and Delivery 
Organisation R&D (NCCSDO) (2005), p. 139; reported in Nunes et al., 2009. 
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Intramuscular long-acting formulations of antipsychotics (LAIs) were developed with 
the primary aim of controlling this phenomenon (Haddad et al., 2014). Some 
disadvantages of these medications have frequently been highlighted, including pain 
on the injection site, lack of flexibility in dose adjustments, and the patient’s 
perception of stigma and coercion (Brissos et al., 2014). However, relevant 
advantages emerged as well. For instance, these formulations allow the complete 
tracking of drug intake, lowering the risk of self-medication and harmful drug use 
(Narasimhan et al., 2007; Brissos et al., 2014), and have also been claimed to prevent 
acute adverse events and relapses due to sudden drug interruptions (Moncrieff, 
2006). The main advantages and disadvantages of LAIs are reported in Table 1. 
 
Table 1. Summary of the main advantages and disadvantages of LAIs. 
Advantages Disadvantages 
 Complete adherence traceability; 
 Lower risk of disproportionate 
medication intake (on voluntary or 
involuntary basis); 
 Closer monitoring of the patient; 
 Higher bioavailability: it is easier to 
detect and maintain the minimum 
effective dose; 
 No risk of symptoms of sudden 
medication interruption; 
 Practicality: less time dedicated to the 
therapy (including going to retrieve the 
prescription, going the pharmacy, 
remember to take the oral medication 
one or more times every day); 
 Possible reduction conflicts with parents 
and other family members, who are 
frequently required (implicitly or 
explicitly) to supervise the correct intake 
of medications.  
 Pain and lesions in the site of injection 
(particularly for oily preparations); 
 Slow titration; 
 Slow resolution of possible adverse events 
after suspending the medication; 
 Less flexibility in personalizing the overall 
dose; 
 Post-injection dysphoria; 
 Post-injection delirium/sedation syndrome 
(olanzapine); 
 Perception of a coercive or even punitive 
intent by administering of the medication; 
 Perception of LAI as stigmatizing medications. 
 
When comparing the risk of relapse between LAI and oral antipsychotics, 
observational studies (including prospective, retrospective and mirror-image studies) 
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generally showed a clear advantage of the former (Tiihonen et al. 2006; Tiihonen et 
al., 2011; Brnabic et al. 2011; Bitter et al., 2013), also when combined in meta-
analyses (Kirson et al., 2013; Kishimoto et al., 2013). On the contrary, randomized 
controlled trials (RCTs) produced controversial evidence. A meta-analysis by Leucht 
and colleagues (Leucht et al., 2011) showed that outpatients taking LAIs had a lower 
risk of relapse, as compared to the oral group (10 RCTs of at least one year of 
follow-up; 1672 patients; relapse rate: RR 0.70, 95% CI 0.57 to 0.87), while another 
meta-analysis (Kishimoto et al., 2014), which included also studies with shorter 
follow-up periods and recruiting inpatients, did not show significant differences 
between the two antipsychotic formulations (21 RCTs; 4950 patients; relapse rate: 
RR 0.93, 95% CI 0.80 to 1.08). Such conflicting data may be at least partially 
explained by relevant methodological limitations of RCTs in these particular patients 
(Ostuzzi and Barbui, 2016; Fagiolini et al., 2017). As a matter of fact, these studies 
are particularly prone to selection bias, considering that recruited patients must 
adhere to rigid therapeutic schedules (for example, double-dummy procedures) and 
should therefore have relatively high levels of adherence. This bias might be 
responsible for a high degree of indirectness of RCTs, hampering their 
generalizability to real-world clinical practice. On the other hand, observational 
studies may have some advantages in terms or external validity, as a large number of 
patients from real-world settings can be recruited and can undergo longer follow-up 
periods (Kane et al., 2013).  
Qualitative studies exploring the subjective experience of patients prescribed with 
LAIs contributed to rethink the possible role of perceived stigmatization associated 
with these formulations. In many cases, patients emphasized the enhanced 
practicality of LAIs, a reduced perception of being controlled by parents or other 
family members, and an overall better overall attitude toward medications (Patel et 
al., 2009; Das et al., 2014; Walburn et al., 2001; Iyer et al., 2013; Pietrini et al., 2016). 
As a result of this growing body of knowledge, the most influential clinical guidelines 
agree in recognizing LAIs as (a) a valid tool for preventing disease relapses and 
optimizing adherence; (b) a choice which is justified from the early phases of disease; 
(c) a practical approach to simplify the routine of patients, which should be therefore 
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always discussed and presented as an alternative option to oral antipsychotics. 
Excerpts from some of the most recent guidelines are reported in Table 2. 
 
Table 2. Synthesis of the most recent guidelines on LAI prescription 
Source Year Excerpts from the recommendation 
BAP (British Association 
of Psychopharmacology) 
(Barnes et al., 2011) 
2011  A depot/long-acting injection formulation should be considered 
when this is preferred by the patient, previous non-adherence has led 
to frequent relapse or the avoidance of non-adherence is a clinical 
priority. 
 The place of antipsychotic depot/long-acting injections for first-
episode schizophrenia [and for the treatment of aggressive behavior] 
remains uncertain 
SIGN (Scottish 
Intercollegiate Guidelines 
Network) (SIGN, 2013) 
2013  Individuals with schizophrenia who request depot and those with 
medication adherence difficulties should be offered maintenance 
treatment with depot antipsychotic medication. 
 Service users should be given the option of oral or depot medication, 
in line with their preference. 
NICE (National Institute 
for health and Clinical 
Excellence) (NICE, 2014) 
2014  Consider offering depot/long-acting injectable antipsychotic 
medication to people with psychosis or schizophrenia: (a) who would 
prefer such treatment after an acute episode; (b) where avoiding 
covert non-adherence (either intentional or unintentional) to 
antipsychotic medication is a clinical priority within the treatment 
plan. 
 When initiating LAI [...] take into account the same criteria 
recommended for the use of oral antipsychotic medication [...]. 
RANZCP (Royal 
Australian and New 
Zealand College of 
Psychiatrists) (Galletly et 
al., 2016) 
2016  Long-acting injectable antipsychotic agents should be offered to 
patients early in the clinical course of schizophrenia. 
 Consider the use of long-acting injectable antipsychotic medicines if: 
- the individual prefers a long-acting injectable medicine, 
- adherence has been poor or uncertain, 
- there has been a poor response to oral medication. 
 Long-acting injectable antipsychotic agents, particularly SGAs, 
provide an important treatment option in all phases of the disease for 
people whose adherence to oral treatment is poor. 
Very few available evidence focuses on the pharmacological and clinical 
characteristics of single LAIs, the choice of which can be influenced by several 
 10 
 
considerations. First, because of pharmacokinetic features, LAIs may not be simply 
comparable to oral counterparts in terms of efficacy and tolerability (Ereshefsky & 
Mascarenas, 2003), although this hypothesis failed to be confirmed by data from 
clinical studies (Ostuzzi et al., 2017a). Second, beside the known differences between 
antipsychotics (Leucht et al., 2013), the tolerability of LAIs may be influenced by 
other pharmacological features (Whyte and Parker, 2016), including the type of 
preparation of the injection (oily preparations of FGA LAIs are more likely to have a 
locally irritant effect), the volume of injected medication, the time required for 
reaching the steady state, the absorption rate (and therefore the interval between 
administrations), and also some mandatory clinical precautions (e.g. the necessity of a 
three-hour clinical monitoring for patients administered with olanzapine pamoate) 
(see Table 3). 
 
Table 3. Main pharmacological characteristics of LAIs (adapted from Whyte and Parker, 2016). 
Medication 
Preparation for 
the injection 
Frequency of 
administration 
Time to reach 
the steady state 
(approximate) 
Notes 
Haloperidol 
decanoate 
Sesame oil 
preparation 
4 weeks 12-16 weeks - 
Fluphenazine 
decanoate 
Sesame oil 
preparation 
2-5 weeks 12 weeks  - 
Zuclopenthixol 
decanoate 
Vegetal oil 
preparation 
2-4 weeks 8 weeks  - 
Risperidone 
long-acting 
Watery 
preparation 
2 weeks 8 weeks  - 
Paliperidone 
palmitate 
Watery 
preparation 
4 weeks 20 weeks  - 
Olanzapine 
pamoate 
Watery 
preparation 
2-4 weeks 12 weeks  
Mandatory 3-
hour clinical 
monitoring  
Aripiprazole 
long-acting 
Watery 
preparation 
4 weeks 20 weeks  - 
In order to pragmatically inform this choice, randomized clinical trials comparing 
two or more LAIs head-to-head would be of relevance. Currently only few studies 
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have been conducted, and they did not show relevant differences between LAIs, with 
the possible exception of aripiprazole long-acting, which was superior in terms of 
quality of life, efficacy and tolerability when compared with paliperidone palmitate 
(Naber et al., 2015) (Table 4). Of notice, only this study included quality of life as the 
primary outcome. Considering this lack of evidence, NICE guidelines (NICE, 2014) 
explicitly recommend to take into account the same criteria applied for the choice of 
oral antipsychotic medication when beginning a LAI. 
 
Table 4. Synthesis of randomized controlled trials comparing LAIs head-to-head 
First author, 
year 
Comparison  Main study characteristics Synthesis of results 
Li et al., 2011 PALI vs. RIS OL; n=452; dia=SCZ; 
FU=13 
No efficacy and tolerability 
differences. 
Pandina et al, 
2011 
PALI vs. RIS DB; n=259; dia=SCZ; 
FU=13 
No efficacy and tolerability 
differences. 
McEvoy et al., 
2014 
PALI vs. ALO DB; n=311; dia=SCZ/SCZ-
AFF at high relapse risk; 
FU=24 
No efficacy differences. Different 
tolerability profiles emerged. 
Naber et al., 
2015 
PALI vs. ARI OL; n=295; dia=SCZ; 
FU=28 
ARI was superior in terms of 
quality of life, efficacy and 
tolerability. 
Legend: PALI=paliperidone; RIS=risperidone; ALO=haloperidol; ARI=aripiprazole; n=number of 
included patients; dia=diagnosis; SCZ=schizophrenia; SCZ-AFF=schizo-affective syndrome; 
FU=weeks of follow-up; OL=open-label design; DB=double-blind design. 
 
 
 
Evidence from the first decade of 2000 showed that LAIs were generally prescribed 
to severely ill patients, with long-lasting disease, frequent relapses, low insight of 
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disease and poor adherence to treatments, or to patients with behavioral issues, 
impulsivity, aggressiveness (including not only patients with psychosis, but also 
mental organic conditions, such as mental retardation, dementia and substance 
abuse) (Svedberg et al., 2003; Shi et al., 2007; Waddell and Taylor, 2009). Since then, 
many factors contributed to change the scenario. First, most second-generation LAIs 
(SGA-LAIs) were introduced on the market only in the last decade (with the only 
exception of risperidone, available in Europe from 2003) (Citrome, 2013; Ostuzzi et 
al., 2017b). Second, growing evidence supported the role of antipsychotics (and 
SGAs in particular) not only for schizophrenia or other chronic psychoses, but also 
for affective disorders (Cipriani et al., 2011; Gigante et al., 2012; Kishi et al., 2016). 
Third, many authors claimed the need for a renewed view on the potential benefits 
of LAIs. According to this perspective, LAIs are generally underused, but may in fact 
provide benefits to a broader number of patients, including in particular younger 
patients, at early stages of disease, and not only patients with a longstanding chronic 
disease, frequent relapses, low adherence and poor insight (Patel et al., 2005; 
Altamura et al., 2012; Maia-de-Oliveira et al., 2013; Stahl, 2014; Heres, 2014; 
Carpenter and Buchanan, 2015; Stevens et al., 2016). This “paradigm change” is 
claimed on the basis of new insights on: 
a. the long-term impact of the early interruption of antipsychotic treatments 
(Stevens et al., 2016; Stahl, 2014;  Kirschner et al., 2013); 
b. the practicality of LAIs and therefore their impact on quality of life as 
perceived by patients (Walburn et al., 2001; Iyer et al., 2013; Montemagni et 
al., 2016), in contrast with a rooted idea of LAIs as coercive and stigmatizing 
medications (James et al., 2012; Patel et al., 2010; Stevens et al., 2016); 
c. a possibly enhance tolerability of LAIs over their oral counterparts due to 
favorable pharmacokinetic features (Ereshefsky and Mascarenas, 2003; 
Mannaert et al., 2005; Fleischhacker et al., 1994; Moncrieff, 2006). This 
hypothesis still need to be fully verified, although it is not supported by data 
from available RCTs (Ostuzzi et al., 2017a). 
Although in the last fifteen years we witnessed a growing interest for LAI 
medications in scientific literature, only few original studies on prescribing patterns 
have been conducted in recent years (Rossi et al., 2012; Morrato et al., 2015; Singh et 
al, 2016; Lee et al., 2017; Decuypere et al., 2017; Pilon et al., 2017; McCreath et al., 
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2017). Furthermore, the generalizability of these studies is limited by heterogeneous 
methodology and inclusion criteria, as well as a limited number of patients recruited. 
Therefore, it is not clear whether and how the advocated paradigm shift was 
implemented in real-world clinical practice. 
In conclusion, current scientific evidence on LAIs efficacy produced conflicting data, 
raising clinical and methodological issues. This scientific knowledge is particularly 
complex to interpret and to translate into straightforward guidelines for clinicians. 
Alongside with efficacy data from clinical trials and meta-analysis, observational and 
descriptive studies, possibly including qualitative outcomes on subjective perception 
and attitude toward medication, may be of great value for helping the clinician in 
identifying who may really benefit from a LAI under ordinary clinical practice. 
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Chapter 2 
Materials and methods 
 
Research Aims 
The STAR Network “Depot” is composed by a cross-sectional phase and a 
subsequent longitudinal phase. The cross-sectional phase (already concluded) aimed 
at assessing how the change of scenario around the clinical role of LAIs was received 
and implemented into real-world Psychiatry Services in Italy. The longitudinal phase 
(still ongoing) aims at evaluating the impact of LAIs on a number of outcomes 
pertaining symptom profiles and subjective perception of treatments. 
In particular, the following aims were pursued: 
1. Describing the socio-demographic characteristics and the main clinical features 
(including symptom profiles, adherence and attitude towards treatments) of a 
population of patients beginning a new treatment with a LAI; 
2. Evaluating whether these characteristics differ according to the type of LAI; 
3. Describing the characteristics of prescribers and to examine which reasoning and 
evaluation underpinned the choice of a LAI; 
4. Evaluating, after 6 and 12 months of follow-up, the impact of LAIs using the 
following outcomes: (a) symptom profiles; (b) treatment adherence; (c) 
hospitalizations frequency; (d) rate of patients prematurely withdrawing the 
treatment. On a descriptive and explorative purpose, possible associations 
between these outcomes and the main socio-demographic and clinical 
characteristics of patients will be assessed. 
 
The STAR Network 
Participating centers are part of the STAR Network (Servizi Territoriali Associati per la 
Ricerca), which is a consortium of clinicians and researchers from Community 
Psychiatric Services all over Italy. The main aim of this group it to perform pragmatic 
studies on clinically relevant topics, by gathering data from real-world practice. The 
activities of the STAR Network are coordinated by the Unit of Clinical 
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Psychopharmacology, Section of Psychiatry, University of Verona (Prof. Corrado 
Barbui). In recent years this group contributed to provide new insights on relevant 
aspects related to the field of psychopharmacology, including the use of lithium for 
patients at risk of suicide, the combination of antipsychotics for treatment-resistant 
patients, and the risk of QTc prolongation of psychotropic medications (Barbui et al., 
2011; Girlanda et al., 2014; Nosé et al., 2016). All of the STAR Network studies were 
conducted independently, without industry funding or support. 
 
Study design 
This is an observational, longitudinal and multicenter study. Patients referring to the 
participating Community Psychiatry Services and beginning a LAI were consecutively 
enrolled over a period of 12 months (cross-sectional phase). The follow-up phase 
(currently ongoing) includes two follow-up evaluations at 6 and 12 months. 
The present thesis is focused on results from the cross-sectional phase of the study, 
which corresponds to the aims 1 and 2, while the follow-up phase of the study is 
currently ongoing. 
 
Treatments 
Eight LAIs are currently marked in Italy, with the following therapeutic indications: 
1. haloperidol decanoate (Haldol Decanoate), indicated for the maintenance 
treatment of psychosis; 
2. zuclopenthixol decanoate (Clopixol Depot), indicated for acute and chronic 
dissociative syndromes, as well as other paranoid and hallucinatory syndromes, 
particularly when the clinical picture is characterized by anxiety, restlessness, 
psychomotor hyperexcitability and affective reactions; 
3. fluphenazine decanoate (Moditen Depot), indicated for schizophrenia and manic 
syndromes, and in the long-term treatment of chronic psychosis; 
4. olanzapine pamoate (Zypadhera), indicated for the maintenance treatment of 
adult patients with schizophrenia sufficiently stabilized during acute treatment 
with oral olanzapine; 
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5. risperidone long-acting (Risperdal Consta), indicated for the maintenance 
treatment of schizophrenia in patients currently stabilized with oral 
antipsychotics;  
6. paliperidone palmitate 1-month (Xeplion): indicated for maintenance treatment 
of schizophrenia in adult patients stabilized with paliperidone or risperidone; 
7. paliperidone palmitate 3-months (Trevicta): indicated for the maintenance 
treatment of schizophrenia in adult patients who are clinically stable on 1-
monthly paliperidone palmitate injectable product; 
8. aripiprazole long-acting (Abilify Maintena): indicated for maintenance treatment 
of schizophrenia in adult patients stabilized with oral aripiprazole. 
Perphenazine Enantate (Trilafon Enantate) is no longer available on the market in 
Italy. It is relevant to highlight that LAIs have usually different (and more limited) 
indications as compared to their oral counterparts. Table 5 synthetically shows 
therapeutic indications of LAIs and oral antipsychotics. 
 
 Table 5. Therapeutic indications of LAIs 
 
Drug Form SCZ BIP Acute 
Mania 
DEM Mental 
Retardation 
Notes 
OLA oral X X X   - 
 LAI X     Patients already stabilized 
with oral OLA. 
RIS oral X  X X X Includes aggressiveness in 
dementia and mental 
retardation. 
 LAI X     Patients already stabilized 
with oral RIS. 
ARI oral X X X   Includes mania starting from 
13 years old. 
 LAI X     Patients already stabilized 
with oral ARI. 
PALI oral X     - 
 LAI X     Patients already stabilized 
with oral RIS or PALI. 
HAL oral X X X X X Includes psychomotor 
agitation. 
 LAI X X* X*   Indication: “Psychosis”. 
ZUC oral X X* X X* X - 
 LAI X* X* X* X* X* - 
FLU oral - - - - - Not available in Italy. 
 LAI X X* X   Includes “long-term 
treatment of outpatients with 
chronic psychosis”. 
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Legend: OLA=olanzapine; RIS=risperidone; ARI=aripiprazole; PALI=paliperidone; 
HAL=haloperidol; ZUC=zuclopenthixol; FLU=fluphenazine; SCZ=schizophrenia; BIP=bipolar 
disorder; DEM=dementia; *=unclear because regulatory indications use generic terms and does not 
explicitly refer to diagnosis (e.g. psychomotor hyperexcitability, paranoid syndromes, etc.) 
 
Inclusion criteria  
We included patients of 18 years of age or above, willing to sign an informed 
consent, and beginning a LAI therapy (a) for the first time ever, or (b) after having 
assumed a LAI in the past and having interrupted this medication for at least 3 
months. The simultaneous intake of psychotropic medications (including 
antipsychotics) did not represent an exclusion criterion. Patients were enrolled with 
no restrictions in terms of settings within the Community Psychiatric Service, 
including Hospital Psychiatric wards, daytime community facilities and residential 
facilities. 
 
Tools 
In order to collect socio-demographic and clinical data, the following tools were 
administered at the baseline evaluation:  
 Enrolment form, which includes socio-demographic information (age, sex, 
marital status, living conditions, schooling, employment situation), clinical 
and pharmacological information (year of the first contact with psychiatric 
professionals, psychiatric diagnosis, medical co-morbidities, alcohol or 
psychoactive substance use/dependence, hospital admission in the last 12 
months, characteristics of the LAI prescribed and of other medications 
taken), and characteristics of the clinician who prescribed the LAI (sex, age, 
years of clinical experience); 
 Brief Psychiatry Rating Scale (BPRS) (Overall and Gorham, 1962), compiled 
by the clinician, which assesses overall symptom profiles by measuring 18 
psychiatric symptoms. Each symptom is rated from 1 (lowest intensity) to 7 
(highest intensity). This rating scale has been validated in Italian (Roncone et 
al. 1999; Roncone et al. 2003). The overall level of symptomatology should 
be considered mild, moderate and severe for scores ranging from 31 to 40, 41 
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to 52 and higher than 52, respectively. Beside the total score, we also 
calculated the score of five subscales according to Shafer (2005), namely:  
- affect (anxiety, guilt, depression, somatic);  
- positive symptoms (thought content, conceptual disorganization, 
hallucinatory behavior, grandiosity);  
- negative symptoms (blunted affect, emotional withdrawal, motor 
retardation);  
- resistance (hostility, uncooperativeness, suspiciousness);  
- activation (excitement, tension, mannerisms–posturing). 
 Drug Attitude Inventory 10 items (DAI-10) (Hogan et al., 1983), self-
administered, which measures attitudes toward medications. The score ranges 
between -10 and 10, with higher scores indicating a better drug attitude. 
Positive scores indicate an overall positive attitude toward medications. This 
rating scale has been validated in Italian (Rossi et al. 2001);  
 Kemp’s 7-point scale (Kemp et al. 1996; Kemp et al. 1998) compiled by the 
clinician, which assesses overall adherence to treatments. The score ranges 
from one to seven, with higher scores indicating higher levels of adherence. 
Scores of five and above indicate an overall good acceptance of medications. 
Each enrolled patient will subsequently be assessed at 6 and 12 months with a 
Follow-up form, aimed at gathering information on possible diagnostic and 
therapeutic changes, hospital admissions, LAI interruption or switch, premature 
withdrawal from the study. BPRS, DAI-10 and Kemp’s 7-point scale will be 
administer at each time point. Treatment withdrawal is defined as not assuming the 
LAI for at least 2 consecutive times, whichever the reasons are. Also patients 
withdrawing the treatment during the follow-up will undergo the same evaluation. 
Switching from a LAI to another will not be considered as a withdrawal. 
 
Data management  
After having enrolled the patient, completed forms were sent to the coordinating 
center at the Unit of Clinical Psychopharmacology, Section of Psychiatry, University 
of Verona. Data were archived both as hard copy and electronic form. All study data 
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were entered in a computerised database and stored by the Unit of Clinical 
Psychopharmacology of the University of Verona. The correctness and consistency 
of data was ensured by the double-entry technique and by a set of electronic and 
manual edit checks. The consistency of data between the recruitment and follow-up 
forms and the computerised database will be verified.  
Data collected in the study corresponding to a patient were recorded anonymously. 
Patients were identified by a unique number both in the recruitment and follow-up 
forms, and in the database. Total confidentiality of data was and will be guaranteed 
throughout the entire course of the study, in accordance with the Declaration of 
Helsinki.  
 
Data analysis 
All statistical analyses were performed with STATA 13.0 (STATA Corp, College 
Station, Tex). Descriptive statistic was employed for describing the main 
epidemiological characteristics of the recruited population. Continuous variables 
were expressed as means and standard deviations, while categorical variables were 
expressed as percentages. In order to describe possible associations between clinical 
and socio-demographic characteristics and the class of LAI prescribed, both bivariate 
and multivariate logistic regression analyses were performed. A bivariate analysis 
employing the class of LAI (0=first-generation LAIs; 1=second-generation LAIs) as 
the dependent variable, was applied to a number of variables of clinical relevance. 
Selected continuous and categorical variables were transformed into dichotomous or 
simpler categorical data, in order to directly compare two or more categories of 
clinical relevance. All the following variables were analyzed: mean age, nationality 
(Italians versus non-Italians), living conditions (poor autonomy level versus good 
autonomy level), level of education (diploma/University degree versus other), 
working conditions (employed versus unemployed), diagnosis (schizophrenia 
spectrum versus bipolar disorder versus other diagnosis), mean BPRS score, mean 
BPRS subscales scores (including affective symptoms, positive symptoms, negative 
symptoms, resistance, activation), mean DAI-10 score, mean Kemp’s 7-point scale 
score, mean number of hospitalizations in the last year, mean length of 
hospitalizations, history of compulsory hospitalization, alcohol abuse, substance 
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abuse, presence of medical comorbidity, number of previous depots, number of 
psychotropic drugs in the last year, mean cumulative dose of psychotropic drugs 
taken in the last year expressed as the ratio between the prescribed daily dose (PDD) 
and the defined daily dose (DDD) (Nosé et al., 2008), type of center (academic 
versus non-academic centers), place of recruitment (north versus south-center Italy), 
prescriber’s mean age. As a subsequent step, all variables for which a statistically 
significant association emerged after the bivariate analysis were included as 
independent variables in a first, intermediate multivariate model. A final simpler 
multivariate model included only variables for which a statistically significant 
association emerged from the intermediate model. Regression analyses were based on 
robust estimator of variance (cluster option of STATA vce command) to account for 
the multicenter observational design (Williams, 2000). 
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Chapter 3 
Results of the study 
 
Participating centers 
Thirty-five Italian Community Psychiatric Centers took part to the study (Figure 2). 
Each center received a formal approval from the local Ethics Committee (EC) and 
began patients recruitment. The first patient was recruited in December 2015 and the 
last in May 2017. Participating centers contributed to the recruitment to a different 
extent, with a mean of 12.9 patients for each center (standard deviation (sd) 13.42; 
median 10; range 2-70). The majority of centers (25) recruited in a community, non-
academic, setting. However, the number of patients recruited from academic and 
non-academic centers was equally distributed (54.5% vs. 45.4%, respectively). The 
majority of centers (25) were located in Northern Italy, however the number of 
patients recruited in these centers was only slightly superior to the number recruited 
in Central and Southern Italy (59.4% vs. 40.6%, respectively).  
 
     
Figure 2. Location of recruiting centers 
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Socio-demographic characteristics 
 A total of 451 patients were recruited and included in the analysis (Table 6). In this 
cohort, 177 patients were females (39.2%) and the mean age was 41.8 (standard 
deviation (sd) 13.42). The large majority of patients were Italian citizens (88.2%). The 
most represented foreign countries were Romania (7 patients), Morocco (5 patients) 
and Bangladesh (4 patients). A slight majority of patients showed a low degree of 
autonomy, considering that 50.8% lived with their parents or other relatives, and 6% 
lived in a residential home. A 
possibly higher degree of autonomy 
was observed for those living with 
the spouse/husband and/or 
children (21.1%) and for those 
living alone (22.2%). The education 
level was relatively high, considering 
that 40% of patients had a diploma 
and 9.9% had a university degree, 
while the remaining half of the 
cohort had no more than lower 
secondary education. At the time of 
recruitment 22.2% of patients were 
employed. A large majority of the 
cohort (85%) was not conjugated at 
the time of enrolment in the study. 
 
 
 
 
 
 
 
Table 6. Socio-demographic features  
 
Variables All LAIs, 
n=451 
Age, mean (sd) 41.8 (13.42) 
Age categories, n (%) 
18-30 
31-45 
46-60 
>61 
 
111 (24.6) 
161 (35.7) 
144 (31.9) 
35 (7.8) 
Female, n (%) 177 (39.2) 
Italian, n (%) 390 (88.2) 
Housing conditions, n (%) 
Alone 
With partner and/or children  
With other relatives 
Any residential home 
 
100 (22.2) 
95 (21.1) 
229 (50.8) 
27 (6) 
Marital status, n (%) 
Non-conjugated 
Conjugated 
 
383 (85.1) 
67 (14.9) 
Educational level, n (%) 
Illiterate/no title 
Primary school 
Secondary school 
Diploma 
University degree 
 
7 (1.6) 
27 (6.1) 
189 (42.5) 
178 (40) 
44 (9.9) 
Work, n (%) 
Employed 
Unemployed 
Student 
Retired 
Housewife/other 
 
100 (22.2) 
221 (49) 
15 (3.3) 
68 (15.1) 
47 (10.4) 
N=number of patients; LAIs=long-acting antipsychotics; 
PDD/DDD=prescribed daily dose/defined daily dose; 
BPRS=Brief Psychiaty Rating Scales; DAI-10=; sd=standard 
deviation 
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Clinical features 
In terms of diagnosis, 55.9% of patients suffered from schizophrenia, 16.5% from 
schizoaffective disorder, 18% from bipolar disorder, 6% from personality disorders, 
and the remaining 3.5% from various conditions, including obsessive-compulsive 
disorder and conditions with a medical/organic base (mental retardation, mental 
organic disorders, dementia) (Table 7). At the time of enrollment, patients were 
under the care of a Psychiatry Service from a mean period of 11.9 years (sd 10.04). 
Of those, 13.8% had had a disease duration lower than one year, 22.3% between 2 
and 5 years, 16.5% between 6 and 10 years, and 47.4% of 11 years or more. Sixty-five 
patients (14.4%) had alcohol abuse issues at the time of enrollment, and 90 (20%) 
abused of psychotropic substances, mostly cannabis (76.7%). Overall, 120 patients 
(about 27% of the whole cohort) used alcohol or substances or both. Slightly more 
than one over four patients (28.2%) suffered from at least one physical comorbidity. 
Among those, 37.8% suffered from endocrine, metabolic or nutritional disorders and 
18.1% suffered from cardiovascular disorders. In terms of symptom profiles, the 
mean BPRS score was 48.99 (sd 14.73), with relatively low mean scores at the 
subscales measuring negative symptoms (mean 7.79, sd 3.68), affective symptoms 
(mean 10.53, sd 4.33), resistance (mean 9.40, sd 4.47), and activation (mean 7.62, sd 
3.34), while higher scores emerged in terms of positive symptoms (mean 12.09, sd 
5.41). The mean DAI-10 score was 1.98 (sd 5.35) and the mean Kemp’s 7-point scale 
score was 4.80 (sd 1.44). Three over five patients (59.9%) had at least one hospital 
admission in the last 12 months, and the overall mean number of days of 
hospitalization was 22.7 (sd 19.48). About 20% of patients had at least one 
hospitalization on a compulsory basis.  
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Table 7. Clinical features and symptom profiles 
Variables All LAIs, n=451 
Diagnosis, n (%) 
Schizophrenia 
Schizoaffective disorder 
Substance-related psychosis 
Bipolar disorder 
Obsessive-compulsive disorder 
Personality disorder 
Mental retardation 
Mental organic disorder 
Dementia 
 
251 (55.9) 
74 (16.5) 
2 (0.4) 
81 (18) 
4 (0.9) 
27 (6) 
4 (0.9) 
4 (0.9) 
2 (0.4) 
Time from disease onset, mean years (sd)  11.89 (10.04) 
Alcohol abuse, n (%) 65 (14.4) 
Substance abuse, n (%) 90 (20) 
Substances, n (%) 
Cannabis 
Cocaine 
Other 
 
69 (76.7) 
13 (14.4) 
8 (8.9) 
At least one medical comorbidity, n (%) 127 (28.2) 
Medical comorbidity, n (%) 
Infective disease 
Endocrine/metabolic disease 
Cardiovascular disease 
Neurologic disease 
Gastrointestinal disease 
Other 
 
8 (6.3) 
48 (37.8) 
23 (18.1) 
10 (7.9) 
11 (8.7) 
27 (21.2) 
BPRS, mean (sd) 48.99 (14.73) 
BPRS positive symptoms, mean (sd) 12.09 (5.41) 
BPRS negative symptoms, mean (sd) 7.79 (3.68) 
BPRS affective symptoms, mean (sd) 10.53 (4.33) 
BPRS resistance, mean (sd) 9.40 (4.47) 
BPRS activation, mean (sd) 7.62 (3.34) 
DAI-10, mean (sd) 1.98 (5.35) 
Kemp’s 7-point scale, mean (sd) 4.80 (1.44) 
At least one hospitalization in the last year, n (%) 270 (59.9) 
At least one compulsory hospitalization, n (%) 89 (19.7) 
Length of hospitalizations, mean days (sd) 22.75 (19.48) 
Last year’s cumulative dose of psychotropic drugs: 
PDD/DDD, mean (sd) 
1.80 (2.03) 
LAIs PDD/DDD, mean (sd) 1.34 (1.17) 
Number of previous depots, n (%) 
0 
1 
2+ 
 
316 (70.1) 
103 (22.8) 
32 (8.1) 
n=number of patients; LAIs=long-acting antipsychotics; PDD/DDD=prescribed daily 
dose/defined daily dose; BPRS=Brief Psychiaty Rating Scales; DAI-10=; sd=standard deviation 
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Figure 3. LAIs prescribed 
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risperidone
Pharmacologic features 
At the time of recruitment, most patients were prescribed with paliperidone long-
acting (30.8%), aripiprazole (25.1%), haloperidol decanoate (20.2%) and risperidone 
long-acting (10.2%). A smaller proportion of patients were prescribed with 
fluphenazine (5.8%), olanzapine (3.9%), zuclophentixol (3.5%) and perphenazine 
(0.4%) (Figure 3). For 70.1% of patients this was the first prescription of a LAI. The 
vast majority of patients (91.6%) was taking at least another psychotropic drug orally 
before introducing the LAI. About one over three patients (32.1%) experienced at 
least one adverse event of the antipsychotic medication in the last year, in most cases 
extrapyramidal symptoms (44.1%) and psychic symptoms (23.4%) (sedation, 
difficulty in concentrating, tiredness, etc.). The ratio between the prescribed daily 
dose (PDD) and the defined daily dose (DDD) of psychotropic drugs (including 
antipsychotics, antidepressants, mood stabilizers, benzodiazepines and 
anticholinergic drug) taken in the last year was 1.80 (sd 2.03), meaning that their 
cumulative dose was almost doubled with respect to the dose usually required. Also 
the cumulative dose of LAIs prescribed was higher than the defined daily dose 
(PDD/DDD 1.34, sd 1.17). For the majority of recruited patients (70.1%) this was 
the first LAI ever prescribed. The 22.8% was prescribed with another LAI in the 
past, and the 8.1% with two or more (Table 7). 
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Comparison between classes of antipsychotic 
Table 8 reports the comparison between FGA and SGA LAIs. Raw data for each 
group, the results of the bivariate analysis and the two multivariate models employed 
are reported for a number of clinically relevant variables. The bivariate analysis 
showed that being prescribed with a SGA LAI was significantly more likely in: 
- patients of younger age (OR 0.97, 95% CI 0.95 to 0.98); 
- patients employed (OR 1.81, 95% CI 1.06 to 3.07); 
- patients with a higher score on the subscale of the BPRS measuring affective 
symptoms (OR 1.08, 95% CI 1.03 to 1.14); 
- patients with a higher score on the DAI-10 scale (which indicates an overall 
better attitude towards medications from the point of view of the patient) (OR 
1.05, 95% CI 1.01 to 1.09); 
- patients with a higher score on the Kemp’s 7-point scale (which indicates an 
overall better adherence to medications from the point of view of the clinician) 
(OR 1.05, 95% CI 1.01 to 1.09). 
On the contrary, being prescribed with a SGA LAI was significantly less likely in: 
- patients living alone or with their partner and/or children; in patients with a 
diagnosis of the group “other” (which includes personality disorders, obsessive-
compulsive disorder, substance-related psychosis, mental retardation, mental 
organic disorders and dementia), as compared with the group of patients with 
schizophrenia/schizoaffective disorder (OR 0.38, 95% 0.20 to 0.72);  
- patients with a higher score on the subscale of the BPRS measuring resistance 
(OR 0.95, 95% CI 0.91 to 0.99);  
- patients with a higher number of hospitalizations in the last year (OR 0.82, 95% 
CI 0.69 to 0.99);  
- patients with at least one medical comorbidity (OR 0.61, 95% CI 0.39 to 0.94); 
- patients with a higher number of LAIs prescribed in the past (OR 0.67, 95% CI 
0.50 to 0.90). 
The intermediate multivariate model, which included all previously reported 
significant variables as possible confounders, confirmed a statistically significant 
association only for five of those reported above: 
- younger age (OR 0.97, 95% CI 0.95 to 0.99); 
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- being employed (OR 1.99, 95% CI 1.02 to 3.90); 
- having a diagnosis of the category “other” (OR 0.30, 95% CI 0.14 to 0.67); 
- having a higher score on the BPRS subscale measuring affective symptoms (OR 
1.10, 95% CI 1.05 to 1.15); 
- a higher number of LAIs prescribed in the past (OR 0.73, 95% CI 0.55 to 0.96). 
The final multivariate model, which included only these five variables as possible 
confounders, confirmed for all of them a statistically significant association with the 
dependent variable: 
- younger age (OR 0.97, 95% CI 0.95 to 0.98); 
- being employed (OR 2.01, 95% CI 1.14 to 3.56); 
- having a diagnosis of the category “other” (OR 0.28, 95% CI 0.13 to 0.60); 
- having a higher score on the BPRS subscale measuring affective symptoms (OR 
1.09, 95% CI 1.04 to 1.14); 
- a higher number of LAIs prescribed in the past (OR 0.69, 95% CI 0.52 to 0.93). 
In synthesis, the two subsequent logistic regression models allowed to detect a robust 
association between the prescription of SGA LAIs and younger age; being employed; 
having a diagnosis different from schizophrenia, schizoaffective or bipolar disorder; 
having a higher score on the BPRS affective subscale; having a higher number of 
LAIs prescribed in the past. 
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Table 8. Bivariate and multivariate comparison between FGAs and SGAs 
Variables 
SGAs LAIs, 
n=316 
FGAs LAIs, 
n=135 
SGAs vs. FGAs 
unadjusted OR  
[95% CI] 
adjusted OR* 
[95% CI] 
adjusted OR** 
[95% CI] 
Age, mean (sd) 40.08 (13.16) 45.89 (13.18) 0.97 [0.95 to 0.98] 0.97 [0.95 to 0.99] 0.97 [0.95 to 0.98] 
Female, n (%) 117 (37.03) 60 (44.44) 0.73 [0.49 to 1.11] - - 
Italian, n (%) 268 (87.01) 122 (91.04) 1.52 [0.77 to 2.99] - - 
Lives alone or with 
partner/children, n (%) 
126 (39.87) 69 (51.11) 0.63 [0.42 to 0.95] 0.85 [0.49 to 1.46] - 
Diploma or University 
degree, n (%) 
164 (52.40) 58 (43.94) 1.40 [0.93 to 2.11] - - 
Employed, n (%) 79 (25) 21 (15.56) 1.81 [1.06 to 3.07] 1.99 [1.02 to 3.90] 2.01 [1.14 to 3.56] 
Diagnosis, n (%) 
Schizophrenia spectrum 
Bipolar disorder 
Other 
 
233 (74.20) 
60 (19.11) 
21 (6.69) 
 
92 (68.15) 
21 (15.56) 
22 (16.30) 
 
ref. 
1.13 [0.65 to 1.96] 
0.38 [0.20 to 0.72] 
 
ref. 
1.11 [0.53 to 2.30] 
0.30 [0.14 to 0.67] 
 
ref. 
1.09 [0.52 to 2.31] 
0.28 [0.13 to 0.60] 
BPRS, mean (sd) 49.27 (15.38) 48.35 (13.11) 1.00 [0.99 to 1.02] - - 
BPRS affective symptoms, 
mean (sd) 
10.95 (4.44) 9.55 (3.92) 1.08 [1.03 to 1.14] 1.10 [1.05 to 1.15] 1.09 [1.04 to 1.14] 
BPRS positive symptoms, 
mean (sd) 
12.16 (5.64) 11.92 (4.85) 1.01 [0.97 to 1.05] - - 
BPRS negative symptoms, 
mean (sd) 
7.93 (3.75) 7.45 (3.49) 1.04 [0.98 to 1.10] - - 
BPRS resistance, mean (sd) 9.08 (4.48) 10.13 (4.37) 0.95 [0.91 to 0.99] 0.96 [0.90 to 1.03] - 
BPRS activation, mean (sd) 7.61 (3.46) 7.65 (3.07) 1.00 [0.94 to 1.06] - - 
DAI-10, mean (sd) 2.38 (5.25) 1.07 (5.47) 1.05 [1.01 to 1.09] 1.02 [0.96 to 1.07] - 
Kemp’s 7-point scale, 
mean (sd) 
4.93 (1.40) 4.48 (1.50) 1.24 [1.08 to 1.44] 1.02 [0.78 to 1.35] - 
N. of hospitalizations in 
the last year, mean (sd) 
0.79 (1.07) 1.04 (1.11) 0.82 [0.69 to 0.99] 0.86 [0.66 to 1.11] - 
Length of hospitalizations 
(days), mean (sd) 
13.38 (19.33) 14.33 (17.32) 1.00 [0.99 to 1.01] - - 
At least one compulsory 
hospitalization, n (%) 
56 (31.82) 33 (35.11) 0.86 [0.51 to 1.46] - - 
Alcohol abuse, n (%) 44 (13.92) 21 (15.56) 0.88 [0.50 to 1.54] - - 
Substance abuse, n (%) 63 (19.94) 27 (20.00) 1.00 [0.60 to 1.65] - - 
At least one medical 
comorbidity, n (%) 
79 (25.08) 48 (35.56) 0.61 [0.39 to 0.94] 0.82 [0.54 to 1.26] - 
Number of previous LAIs, 
mean (sd) 
0.33 (0.65) 0.52 (0.70) 0.67 [0.50 to 0.90] 0.73 [0.55 to 0.96] 0.69 [0.52 to 0.93] 
Number of psychotropic 
drugs in the last year, mean 
(sd) 
1.35 (0.97) 1.48 (1.12) 0.88 [0.73 to 1.08] - - 
Last year’s cumulative dose 
of psychotropic drugs: 
PDD/DDD, mean (sd) 
1.88 (2.19) 1.60 (1.59) 1.08 [0.96 to 1.22] - - 
University center, n (%) 169 (53.48) 77 (57.04) 0.86 [0.58 to 1.30] - - 
South-center Italy, n (%) 132 (41.77) 51 (37.78) 1.18 [0.78 to 1.79] - - 
Prescriber’s age, mean (sd) 45.63 (10.36) 46.69 (12.26) 0.99 [0.97 to 1.01] - - 
* the intermediate multivariate model including variables for which a statistically significant association emerged in the bivariate analysis  
** the final multivariate model including variables for which a statistically significant association emerged from the intermediate model  
Bold characters indicate a p-value < 0.05. 
The % reported in parenthesis refers to the ratio calculated respectively on all LAIs (first column), FGA LAIs (second column); SGA 
LAIs (third column) 
n=number of patients; sd=standard deviation; OR=odds ration; CI=confidence interval; BPRS=brief psychiatry rating scale; DAI=drug 
attitude inventory; PDD=prescribed daily dose; DDD=defined daily dose 
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Chapter 4 
Critical appraisal of results 
 
The recruited population included a wide range of socio-demographic and clinical 
characteristics. A relevant part of the cohort met the features typically described in 
older studies (before the broad availability of most SGA LAIs), as patients were 
mostly males in their middle adulthood, with low educational level, no employment, 
a long-standing diagnosis of schizophrenia, and moderate-to-severe level of 
psychopathology (Shi et al., 2007; Barnes et al., 2009; Citrome et al., 2010; Crivera et 
al., 2011; Haddad et al., 2016). At the same time, relatively high functioning levels 
emerged in a surprisingly large part of the population, considering that about 43% of 
patients lived alone or with the partner and/or children, more than one out of five 
patients were employed, and half of the patients had a diploma or a University 
degree. Similar considerations apply to clinical features, considering that, beside a 
large number of patients with chronic conditions and severe symptom profiles, also 
patients with mild-to-moderate levels of symptom profiles were well represented. 
Further, data showed a relatively short course of disease (lower than 5 years) in about 
36% of patients, and an overall good attitude towards medications in 61% of patients 
as perceived by the clinician, and in 59% of patients as perceived by the patients 
themselves. Interestingly, a variety of diagnosis emerged. Almost one out of five 
patients had a bipolar disorder, as expected considering the recently broadened use 
of antipsychotics for affective disorders (Cipriani et al., 2011; Zhou et al., 2015). In 
about 6% of patients the LAI was probably prescribed to manage severe behavioral 
symptoms arising from personality disorders or underlying somatic conditions (such 
as mental retardation or dementia), although the use of antipsychotics in these cases 
is at least controversial, particularly in the long-term (Lieb et al., 2010; Maust et al., 
2015).  
In general, these data seem to confirm the expectation that a broader spectrum of 
individuals is currently prescribed with LAIs as compared to the past. As discussed 
above, highly selected populations from previous studies can be hardly compared 
with the present study, which employed a pragmatic, naturalistic approach, aimed at 
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minimizing patients’ selection and reflect real-world practice as closely as possible. 
However, mean age and gender were generally in line with data from previous studies 
with a catchment timespan including most recently released SGA LAIs (Marcus et al., 
2015; McCreath et al., 2017; Pilon et al., 2017; Gaviria et al., 2017; Decuypere et al., 
2017; Singh et al., 2016; Greene et al., 2017), while other socio-demographic details 
were not available.  
The use of LAIs on a broader number of clinical conditions may raise regulatory 
issues, considering that licensed indications of SGA LAIs are limited only to patients 
with schizophrenia in a maintenance phase with oral antipsychotics. Therefore, SGA 
LAIs were prescribed off-label to all patients without a diagnosis of schizophrenia 
(almost one out of five patients). On the contrary, indications of FGA LAIs are 
much less narrow, often referring to symptom domains rather than specific 
diagnosis, and may therefore be prescribed to patients with several different 
diagnosis. The common off-label prescription of LAIs confirms the already well-
known trend of oral antipsychotics (Driessen et al., 2016). 
Some clinical characteristics of the cohort appeared to be consistent with what 
expected in the general population of patients with chronic psychosis, in particular 
the high prevalence of patients with comorbid physical conditions (about one out of 
four patients had at least one comorbidity, mostly endocrine/metabolic or 
cardiovascular) and with a “dual diagnosis”, considering that one out of four used 
alcohol or substances (Regier et al., 1990; Mitchell et al., 2013). 
In most cases LAIs were prescribed after a period of severe disease relapse, 
considering the high number of patients hospitalized in the previous year, the high 
rate of compulsory admissions, and the long mean length of stay. This may suggest 
that, despite the recommendation of offering LAIs from the early phases of disease 
(NICE, 2014; Galletly et al., 2016), in many cases these formulations are still chosen 
after failed attempts with other treatments. 
More than two out of three patients were prescribed with SGA LAIs. The most 
commonly prescribed medications were paliperidone palmitate (30.8%), aripiprazole 
LAI (25.1%) and haloperidol decanoate (20.2%). These results are in line with data 
from some of the previous studies (Pilon et al., 2017; Greene et al., 2017; Lee et al., 
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2017), although in some other studies rates appeared to be extremely heterogeneous 
(Marcus et al., 2015; McCreath et al., 2017; Dimitropoulos et al., 2017), which is likely 
to be related to a number of factors influencing local prescribing patterns, as well as 
different recruitment timespan of studies (and therefore different availability of SGA 
LAIs). The use of aripiprazole LAI was surprisingly high compared to other recent 
studies (Marcus et al., 2015; McCreath et al., 2017; Pilon et al., 2017; Greene et al., 
2017). The advantages of this medication compared to other antipsychotics have 
been repeatedly stressed: it is relatively safe in terms of motor, metabolic and 
endocrine adversities (in particular it does not alter prolactin levels), and it proved to 
be comparable to other SGAs in terms of efficacy for the treatment of schizophrenia 
(Leucht et al., 2013; Khanna et al., 2014). Further, robust results from a recent meta-
analysis showed a better overall acceptability of aripiprazole LAI as compared to the 
oral counterpart, although the interpretation of this data is still unclear (Ostuzzi et al., 
2017a). On the other hand, paliperidone substantially equals olanzapine and 
risperidone in terms of metabolic effects and prolactin raise (Leucht et al., 2013). Its 
choice over these two medications is likely to be related to an enhanced practicality 
of paliperidone palmitate, considering that risperidone LAI needs a biweekly 
administration, and olanzapine pamoate is burdened by complex regulatory 
requirements. Haloperidol decanoate, besides its possible disadvantages (e.g. motor 
symptoms, QTc prolongation, locally irritant preparations), remains a widely used 
medication in clinical practice, possibly because of its relatively safe metabolic profile 
(Leucht et al., 2013), and the flexibility of the LAI in terms of doses and frequency, 
as compared to other LAIs (including SGAs). 
The logistic multivariate model comparing FGA LAIs and SGA LAIs showed that 
the latter were prescribed significantly more often to younger, employed individuals, 
with a diagnosis schizophrenia or bipolar disorder, with higher levels of affective 
symptoms, and without a previous history of LAI prescription. This profile 
resembles closely the one pictured by those claiming a cultural change in the clinical 
use of LAIs. This trend is similar to what emerged from previous studies, although in 
many cases only FGA LAIs and risperidone LAI were compared (Singh et al., 2016; 
Lammers et al., 2013; Nielsen et al., 2015), the adjustment for confounders was not 
performed (Marcus et al., 2015; Pilon et al., 2017; Nielsen et al., 2015), and social and 
clinical variables possibly associated with the class of LAI were not analyzed. 
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Notably, no significant differences emerged between patients prescribed with FGA 
LAIs and SGA LAIs in terms of overall symptom profiles, adherence and attitudes 
towards medications, both as perceived by psychiatrists (Kemp’s 7-point score) and 
by patients (DAI-10 score). To our knowledge, the study by Singh and colleagues 
(Singh et al., 2016) is currently the only available study employing the DAI (in this 
case, the version with 30 items), and it reached similar conclusions, although in this 
case only FGA LAIs and LAI risperidone were compared. 
As expected according to current trends in literature (Kapur & Remington, 2001; 
Müller-Spahn, 2002; Masan, 2004), SGAs were preferred when targeting affective 
symptoms. This may also reflect the common idea of FGAs as medications 
associated with apathy, lack of initiative, anhedonia, indifference, blunted affect (the 
so-called neuroleptic-induced deficit syndrome) (Schooler, 1994; Kirkpatrick, 2014). 
This study has limitations. First, the cross-sectional design cannot detect a causal 
association between variables, therefore all statistical associations discussed should be 
regarded as merely exploratory. Second, we employed simple and easily administrable 
scales in order to minimize any interference with routine real-world practice, 
although this might have affected the precision in measuring some variables of 
interest, in particular symptom profiles and patients’ attitudes toward medications. 
Third, characteristics of recruiting centers were heterogeneous in terms of 
recruitment settings (community centers, hospital wards, rehabilitation facilities, etc.), 
and they contributed to the recruitment to a different extent. Also, various local 
factors may have strongly influenced prescribing attitudes of each center (e.g. 
hospital internal guidelines, availability of medications, and long-standing local 
habits). This, along with the wide inclusion criteria applied, led to extremely 
heterogeneous features of the population recruited. This reflects the complexity of 
real-world clinical settings, but may at the same time affect the internal validity of 
results (Carlson & Morrison, 2009). In order to address this limitation, we employed 
statistical techniques accounting for inter-center variability. Still, the 
representativeness of the sample, and therefore the epidemiological validity of data, 
remains a relevant element of discussion. 
Some authors found that SGA LAIs are preferred over FGA LAIs mostly by 
younger psychiatrists (Stip, 2017), who may be more prone to promptly translate new 
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scientific insights into clinical practice as compared to older colleagues (Choudhry et 
al., 2005). However, this data was not confirmed by our analysis. Further elements on 
prescribers’ features and reasoning underpinning the choice of a LAI were collected 
during the enrolment phase of the STAR Network “Depot” Study. Relevant insights 
can emerged from the analysis of this data, which were however beyond the overall 
scope of this thesis. 
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Conclusions 
 
 
In the last 10-15 years international experts advocated for a paradigm shift in the use 
of LAIs (Patel and David, 2005; Altamura et al., 2012; Stahl 2014; Stevens et al., 
2016; Maia-De-Oliveira et al., 2013). This alternative interpretation of LAIs took 
place and gradually shaped in parallel with the production and marketing of SGA 
LAIs, and with a progressively widened clinical application of SGAs in general.  
This study showed a notable change in LAIs prescribing habits, as compared with 
previous epidemiological surveys. The advocated cultural change in the use of LAIs 
is currently under way in Italian Community Psychiatric Services, as showed by more 
flexible and heterogeneous prescribing patterns, directed at a wider range of clinical 
conditions and functioning levels. This change appears to be mostly restricted to 
SGA LAIs, while prescribing patterns of FGA LAIs are practically unchanged as 
compared to the past, as they are mostly reserved to older patients, with lower 
functioning levels, previous failed attempts with other antipsychotics, and, 
commonly, behavioral issues.  
Results from this study may arguably suggest that this change in prescribing attitudes 
is underpinned by at least three pre-conditions. First, the increased diffusion of SGA 
LAIs and the progressive characterization of some of them as versatile (use not only 
for schizophrenia, but also in affective disorders), safe (water preparations), and 
tolerable options (low metabolic, endocrine and sedative impact of aripiprazole and, 
to a lesser extent, paliperidone) (Fagiolini et al., 2016; Leucht et al., 2013), compatible 
with higher functioning levels in everyday life. Second, the progressive overcoming 
of old misconceptions (primarily from the prescriber’s side) on stigma and coercion 
of LAIs, which may, on the contrary, ease the burden of stigma associated with oral 
medications (e.g. by avoiding daily monitoring of a correct medication intake by 
parents). Third, the gradual recognition that the practicality of LAIs is a critical added 
value, which may contribute to relieve patients from the daily routine of oral 
medications and its pitfalls, also decentralizing the issue of medications from the 
patient-clinician relationship. 
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In conclusion, a new prescribing approach to LAIs is a matter of growing interest 
not only for academics, but also for psychiatrists working in real-world community 
settings. Although LAIs are broadly accepted as a valuable tool for managing poor 
adherence, their use alone cannot represent an exhaustive response to such a 
multifaceted issue, as confirmed by recent findings (Lee et al., 2017). The extent to 
which these formulations and, more importantly, single LAI medication, can 
contribute to adherence, attitude toward medications, and overall subjective well 
being, still need to be accurately assessed. The follow-up phase of the STAR 
Network “Depot” Study will explore the overall adherence over one year of follow-
up in patients prescribed with LAIs, and how this is influenced by various socio-
demographic, clinical and pharmacological factors, including the antipsychotic 
prescribed. 
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Appendix 2 – Follow-up Form 
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Appendix 3 – Brief Psychiatry Rating Scale (BPRS) 
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Appendix 4 – Drug Attitude Inventory 10-items (DAI-10) 
 
 
 
 61 
 
Appendix 5 – Kemp’s 7-point scale 
 
 
 
